Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Retained Earnings: 2020-2024

Historic Retained Earnings for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to -$237.8 million.

  • Janux Therapeutics' Retained Earnings fell 46.84% to -$319.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$319.4 million, marking a year-over-year decrease of 46.84%. This contributed to the annual value of -$237.8 million for FY2024, which is 40.88% down from last year.
  • As of FY2024, Janux Therapeutics' Retained Earnings stood at -$237.8 million, which was down 40.88% from -$168.8 million recorded in FY2023.
  • Over the past 5 years, Janux Therapeutics' Retained Earnings peaked at -$14.7 million during FY2020, and registered a low of -$237.8 million during FY2024.
  • Over the past 3 years, Janux Therapeutics' median Retained Earnings value was -$168.8 million (recorded in 2023), while the average stood at -$172.3 million.
  • Data for Janux Therapeutics' Retained Earnings shows a maximum YoY crashed of 221.67% (in 2021) over the last 5 years.
  • Janux Therapeutics' Retained Earnings (Yearly) stood at -$14.7 million in 2020, then plummeted by 221.67% to -$47.4 million in 2021, then tumbled by 133.00% to -$110.5 million in 2022, then crashed by 52.77% to -$168.8 million in 2023, then crashed by 40.88% to -$237.8 million in 2024.